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stress conditions was successfully achieved on a C-18 column utilizing 0.01 M Na2HPO4 (pH 4):
acetonitrile in the ratio 80:20 v/v, pumped at a ﬂow rate of 0.5 ml min1 with UV detection at
235 nm. The retention time of clopidogrel was 6.84 min. The method was satisfactorily validated
with respect to linearity, precision, accuracy, selectivity, sensitivity and ruggedness. The response
was linear in the range of 0.2–3.5 lg ml1 with detection limit 0.079 lg ml1. The suggested method
was successfully applied for the analysis of clopidogrel in bulk and in commercial tablets. The
results were favorably compared to those obtained by a reference method. The proposed method
was successfully applied to the content uniformity testing of tablets and for determination of clop-
idogrel in presence of its co-administered drug, acetyl salicylic acid.
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ND license.1. Introduction
Clopidogrel hydrogen sulfate (Clp), methyl (+)-(S)-a-(o-
chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
hydrogen sulfate (SR25990) (Fig. 1), is a new antiplatelet
agent, chemically related to ticlopidine (The United States
Pharmacopeia, 2007; The Merck Index, 2002). It prevents
ischaemic stroke, myocardial infraction and vascular disease
and demonstrated clinical efﬁcacy superior to that of aspirin,
in a large phase III trial (Moshfegh et al., 2000).
It is a carboxylic acid derivative, (+)-(S)-(o-chlorophenyl)-
6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetic acid (SR26334),
which can arise by hydrolysis of the ester group both in vitro
as a result of the action of humidity and temperature in com-
bination, and in vivo, as a result of carboxyesterase, is the
Figure 1 Chemical structure of clopidogrel bisulfate.
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have been reported in literature for the determination of Clp.
Recently, Clp and its impurities have been separated by nor-
mal phase HPLC using a chiral column (Rao et al., 2010).
Also, the non-enzymatic and enzymatic chiral inversion of
Clp has been investigated in vitro using 1H NMR and a chiral
HPLC procedure (Reist et al., 2000).
Moreover, in the same article, a non-stereospeciﬁc HPLC
assay method was also used to monitor the hydrolysis of
Clp. The possible in vivo chiral inversion of carboxylic acid
metabolite of Clp in rats was studied using (S)-a-(1-naph-
thyl)ethyl amine as a derivatization reagent and an HPLC
method with spectrophotometric detection (Reist et al.,
2000). Identiﬁcation and isolation of oxidation impurity of
Clp using HPLC were also reported (Mohan et al., 2008).
HPLC detection of the acid metabolite of Clp (SR26334) in
Wistar rat plasma (Singh et al., 2005), in dog plasma (Yang
et al., 2009), and in human plasma (Bahrami et al., 2008) with
application to bio-equivalence study was reported.
The analysis of carboxylic acid metabolite of Clp in plasma
and serum using GC–MS (Lagorce et al., 1998), LC–MS/MS
(Mitakos and Panderi, 2004; Takahashi et al., 2008) and cap-
illary zone electrophoresis (Karazniewicz-Lada et al., 2010)
methods were reported. Clp was determined in presence of
its metabolite (SR26334) in human plasma by LC–MS (Patel
et al., 2008; Raghundha et al., 2010; Vocilkova et al., 2009),
in tablets by Micellar LC (Belal et al., 2009), HPTLC (Agrawal
et al., 2003), voltammetry (Dermis and Ayadogna, 2010), UV-
spectrophotometry (Zaazaa et al., 2009) and densitometry
(Antic et al., 2007; Zaazaa et al., 2009; Robinson et al., 2007).
The United States Pharmacopoeia (USP) (The United
States Pharmacopeia, 2007) recommended a reversed phase
HPLC method with UV detection at 220 nm for determination
of Clp. Clp was also determined by LC–MS/MS (Shin and
Yoo, 2007) and in its tablets by HPLC with UV detection using
C-8 column (Mitakos and Panderi, 2002) and C-18 column
(Sippel et al., 2008). Clp was also determined with its co-admin-
istered drug, aspirin by UV spectrophotometry (Anandakumar
et al., 2007), chemometric spectrophotometry (Rajput et al.,
2008), HPTLC (Patel et al., 2008) and HPLC-UV detection
(Anandakumar et al., 2002). Two HPLC methods, with UV
detection (Mitakos and Panderi, 2002; Sippel et al., 2008) were
reported for determination of Clp in presence of its forced deg-
radation products. One method (Mitakos and Panderi, 2002)
used a semi-micro C-8 BDS column that is not common in rou-
tine analysis. The second one (Sippel et al., 2008) used C-18 col-
umn which is most commonly used in daily routine analysis but
was sensitive to NaOH and light degraded products only. In
our research a sensitive C-18 column was used for determina-
tion of Clp in presence of all induced degradation products,using NaOH, HCl, H2O2 and light, moreover, small amounts
(0.2–3.5 lg ml1) were determined with good results and short
time (tR of Clp = 6.84 min) compared to other HPLCmethods
(Belal et al., 2009; Sippel et al., 2008). The method was rapid,
accurate, and simple and it can be used for quality control as
well as for content uniformity testing of clopidogrel tablets.
The suggested method was also used for the determination of
Clp with its co-administered drug, acetyl salicylic acid.2. Experimental
2.1. Apparatus
Chromatographic analyses were carried out using LC system
(Perkin–Elmer, USA) consisted of series 200 VacuumDegasser,
series 200 LC pump, series 200 variable-wavelength UV
detector and series 200 autosampler ﬁtted with 200 ll sample
loop. The LC separation was performed on aWaters l Bondap-
ak C-18, 300 · 3.9 mm ID, 10 lm column. The mobile phase
consisted of a mixture of 0.01 M Na2HPO4, adjusted to pH 4
and acetonitrile in the ratio: 80:20 v/v. The mobile phase was ﬁl-
tered by passing through 0.45 lm pore size membrane ﬁlter
(Millipore, Millex-HV, USA) and degassed prior to use. The
samples were also ﬁltered using 0.45 mm disposable ﬁlter. The
ﬂow rate was 0.5 ml min1. All determinations were performed
at ambient temperature with a detection wavelength at 235 nm.
2.2. Materials
2.2.1. Pure standards
(a) Clopidogrel bisulfate: used as received (Sanoﬁ-Synthe-
labo, France).
(b) Acetyl salicylic acid: used as received (El-Nasr Pharm.
Chem. Co., ADWIC, Egypt).
2.2.2. Pharmaceutical dosage forms
The following commercially available pharmaceutical dosage
forms were analyzed:
(1) Myogrel tablets are labeled to contain clopidogrel
bisulfate equivalent to 75 mg of clopidogrel, manufac-
tured by ADWIA Co., SAE, 10th of Ramadan City,
Egypt, Batch No. 080243.
(2) Stroka tablets are labeled to contain clopidogrel bisul-
fate equivalent to 75 mg of clopidogrel, manufactured
by Multi-APEX Pharma Co., SAE, Badr City, Cairo,
Egypt, Batch No. 2300809.2.3. Chemicals and reagents
All chemicals used throughout this work were of analytical
grade and the solvents were of HPLC grade:
(a) Acetonitrile and methanol (Merck, Germany).
(b) Hydrochloric acid (BDH, Germany).
(c) Sodium hydroxide (BDH, Germany).
(d) Hydrogen peroxide (Winlab, UK).
(e) Dibasic sodium phosphate (Winlab, UK).
(f) Ortho phosphoric acid (BDH, Germany).
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Stock standard solutions of clopidogrel bisulfate and acetyl
salicylic acid were prepared in methanol of concentration
0.5 mg ml1 for each separately. Working solutions were pre-
pared by serial dilution of the stock solution with the mobile
phase.
2.5. General assay procedure
2.5.1. Preparation of the calibration graph
Working solutions containing 0.2–3.5 lg ml1 of Clp were pre-
pared by serial dilution of aliquots of the stock solution and
triplicate 10 ll injections were made of each solution and the
peak areas of Clp were plotted against the corresponding con-
centration in lg ml1 to obtain the calibration graph. Alterna-
tively, the corresponding regression equation was derived.
2.5.2. Analysis of bulk substance
The method mentioned above was applied to the determina-
tion of the purity of Clp raw material. The percentage recover-
ies were calculated by referring to the calibration graph
previously prepared or applying the regression equation.
2.5.3. Procedure for preparation of degradation products
Degradation products were prepared by dissolving 25 mg of
Clp in 10 ml methanol and adding 40 ml of 1 M HCl, of 1 M
NaOH and of 5% (v/v) H2O2, each separately in a 100 ml vol-
umetric ﬂask. The solution mixtures were heated in a water
bath at 80 C for 1 h, neutralized with 2 M NaOH and 2 M
HCl for the acidic and alkaline degradation, respectively.
The volumes were completed with methanol and working solu-
tions were diluted with the mobile phase and the steps were fol-
lowed as described under ‘‘general assay procedure’’.
2.5.4. Analysis of dosage forms
Ten tablets were accurately weighed, ﬁnely pulverized and
thoroughly mixed. An amount corresponding to 50 mg of
Clp free base was weighed and transferred into a beaker,
80 ml of methanol were added and the mixture was sonicatedFigure 2 Clopidogrel and NaOH defor 30 min in an ultrasonic bath and then ﬁltered into a 100-ml
volumetric ﬂask and completed to volume with methanol. Ali-
quots of this solution were successively diluted with the mobile
phase and proceeded as mentioned above. The nominal con-
tent of the tablets was calculated either from the calibration
graph or from the regression equation.
2.5.5. Content uniformity testing
The same procedure applied for the analysis of Clp in tablets
was followed using one tablet, as a sample. Ten tablets of each
dosage were analyzed and the uniformity of their contents was
tested by applying the ofﬁcial USP (The United States Phar-
macopeia, 2007) guidelines.
2.5.6. Preparation of synthetic mixtures for determination of
co-administered drug
Acetyl salicylic acid (0.5 mg ml1) was prepared in methanol.
Working solutions were prepared by diluting the stock solu-
tion with the mobile phase. Synthetic mixtures were prepared
by adding known amounts of Clp and acetyl salicylic acid
and they were analyzed using the procedure outlined above.
The mean percentage recoveries and relative standard devia-
tions were calculated.3. Results and discussion
The proposed method permits the separation of Clp from its
degradation products using HCl, NaOH, H2O2 and light. It
also permits the quantitation of Clp in commercial tablets; it
was possible to perform the content uniformity testing. Figs.
2–4 show chromatograms indicating good resolution of Clp
and its degradation products. The proposed method offers
high sensitivity, as about 0.079 lg ml1 of Clp could be de-
tected accurately.
3.1. Chromatographic performance
A well-deﬁned symmetrical peak was obtained upon measur-
ing the response of eluent and the optimized conditions aftergradation product chromatogram.
Figure 3 Clopidogrel and HCl degradation product chromatogram.
Figure 4 Degradation of clopidogrel in H2O2.
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following sections.
3.1.1. Choice of column
Columns from different sources were evaluated. Three differ-
ent columns were used for performance investigation:
(a) Waters l Bondapak, C-18, 300 · 3.9 mm, 10 lm (USA).
(b) Nova-pak, C-18, 300 · 3.9 mm, 4 lm (USA).
(c) Spherical, C-18, 150 · 3.9 mm, 5 lm (USA).
The experimental studies revealed that the ﬁrst column was
more suitable, since it produced the best chromatographic per-
formance and acceptable peak characteristic including tailing
factor, number of theoretical plates, capacity factor, high res-
olution and a very good sensitivity.
3.1.2. Choice of appropriate wavelength
The UV detector response of Clp was studied and the best
wavelength was found to be 235 nm showing the highest
sensitivity.3.1.3. Chromatographic characteristics
Table 1 shows the different compositions of the mobile phase,
pH, and the ﬂow rate. As indicated from the table, the compo-
sition of mobile phase; acetonitrile/phosphate buffer (pH 4)
with ratio 20:80 v/v and a ﬂow rate of 0.5 ml min1 were the
appropriate conditions that were giving well-resolved peaks
and highest number of theoretical plates.
3.2. Validation of the method
The optimal chromatographic separation conditions are:
Column: Waters l Bondapak C-18, 300 · 3.9 mm, 10 lm.
Mobile phase: a solution containing 0.01 M Na2HPO4 (pH
4) and acetonitrile in the ratio 80:20 v/v.
Flow rate: 0.5 ml min1.
Detector wavelength: 235 nm.3.2.1. Degradation studies
In order to assure the selectivity and provide an indication of
the stability-indicating properties of the proposed method,
Table 1 Effect of experimental parameters on the chromato-
graphic performance of clopidogrel bisulfate.
Parameters Retention time
(min) ± SDa
Number of theoretical
plates (N)
pH
3 3.27 ± 0.010 2970
3.5 6.09 ± 0.018 5133
4 6.05 ± 0.023 6507
4.5 6.01 ± 0.021 1627
5 5.44 ± 0.019 2959
Acetonitrile ratio (%)
10 3.25 ± 0.015 1878
15 5.23 ± 0.025 6102
20 6.05 ± 0.023 6507
25 5.68 ± 0.025 6238
30 4.26 ± 0.024 5999
40 3.12 ± 0.031 3218
Flow rate (ml min1)
0.5 6.84 ± 0.024 8416
0.8 6.12 ± 0.018 5828
1.0 5.64 ± 0.032 4936
1.2 4.42 ± 0.027 3845
1.5 3.45 ± 0.028 2113
a Average of three values.
Table 2 Recovery of clopidogrel bisulfate after stress
degradation.
Condition Time (h) Clp (recovery %) tR (min) ± SD
a
1 M HCl 1 78 3.27 ± 0.020
1 M NaOH 1 42 3.29 ± 0.052
5% (v/v) H2O2 1 80 2.85 ± 0.019
Light 7 (days) 98.72 –
a tR of the degraded products, average of three values.
Table 3 Relative retention times of the degraded products
and acetyl salicylic acid.
Compound tR ± SD (% RSD) Relative tR
a
Clopidogrel 6.83 ± 0.027 (0.395) –
Deg. with HCl 3.27 ± 0.020 (0.612) 0.4788
Deg. with NaOH 3.29 ± 0.052 (1.581) 0.4817
Deg. with H2O2 2.85 ± 0.019 (0.667) 0.4173
Acetyl salicylic acid 3.44 ± 0.054 (1.570) 0.5029
a With respect to clopidogrel.
Table 4 Accuracy and precision data for clopidogrel using the
proposed method.
Parameters Clp concentration (lg ml1)
0.5 1 2
Intra-day 98.44 101.39 100.81
100.34 101.01 99.08
101.56 100.73 101.12
Mean (x) 100.11 101.04 100.34
SD 1.57 0.33 1.10
% RSD 1.57 0.33 1.10
% Er 0.91 0.19 0.64
Inter-day 99.84 101.34 102.11
100.65 100.58 101.82
102.04 101.48 100.46
Mean (x) 100.84 101.13 101.46
SD 0.24 0.48 0.88
% RSD 1.23 0.48 0.87
% Er 0.71 0.28 0.50
Each result is the average of three separate determinations.
Intra-day: within the day.
Inter-day: consecutive days.
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stress conditions, with 1 M HCl, 1 M NaOH, and 5% (v/v)
H2O2 at 80 C for 1 h. Moreover, a solution of Clp in metha-
nol was exposed to diffused day light for a period of 7 days,
Figs. 2–4 show the retention times of the degraded products.
The acid stressed samples showed approximately (22%)
degradation (tR = 3.27 min), the base stressed samples showed
approximately (58%) degradation (tR = 3.29 min) and Clp in
5% (v/v) H2O2 showed 20% degradation and tR = 2.85 min.No signiﬁcant degradation was observed in samples of Clp
that were left in day light for 7 days.
Table 2 shows the concentration of Clp after stress degrada-
tion and the relative retention times of the degraded products
to Clp are shown in Table 3.
As indicated from Table 3, the relative retention times are
less than 0.5; this means that well-separated peaks of Clp
and its degraded products were obtained under the chromato-
graphic conditions discussed.
3.2.2. Concentration ranges and calibration graphs
Under the above-described experimental conditions, a linear
relationship was established by plotting Clp concentrations
against the corresponding peak areas. The concentration range
was found to be 0.2–3.5 lg ml1. Linear regression analysis of
the data gave the following equation:
P ¼ 11808:98C 52:371 ðr ¼ 0:9996Þ
whereC is the concentration of Clp in lg ml1 and P is the peak
area. Statistical analysis (Miller and Miller, 1993) of the data
gave: Sb = 134.1648, Sa = 282.4196, where Sb and Sa are the
standard deviations of slope and intercept, respectively.
3.2.3. Limit of quantitation (LOQ) and limit of detection
(LOD)
LOQ was determined by establishing the lowest concentration
that can be measured according to ICH Q 2 recommendations
(ICH Q 2, 2005) below which the calibration graph is non lin-
ear and was found to be 0.2 lg ml1. LOD was determined by
establishing the minimum level at which the analysis can be
reliably detected (S/N = 3); it was found to be 0.079 lg ml1.
3.2.4. Accuracy and precision
The proposed method was evaluated by studying the accuracy
as percent relative error (% Er) and precision as percent rela-
tive standard deviation (% RSD) using three preparations with
suitable concentrations, as shown in Table 4. The intra-day
Table 5 Statistical analysis of the results obtained by the proposed and reference methods for pure samples of clopidogrel bisulfate.
Parameters Proposed method Reference methoda
Concentration (lg ml1) Recoveryb (%) Concentration (lg ml1) Recoveryb (%)
0.2 97.34 4 98.84
0.5 98.82 8 101.73
1.0 101.42 12 99.78
1.5 100.35 16 102.52
1.8 101.22 20 101.85
2.0 99.56
2.2 98.78
2.5 100.46
3.0 99.88
3.5 101.65
N 10 5
Mean (x) 99.95 100.94
SD 1.36 1.56
Variance 1.86 2.43
Student’s t-value 1.27 (2.16)c
Variance ratio F-value 1.31 (3.63)c
a Belal et al. (2009).
b Each result is the average of three separate determinations.
c Tabulated t and F values at p= 0.05 (Miller and Miller, 1993).
Table 6 Assay of clopidogrel bisulfate in tablets using the proposed and reference methods.
Parameters Myogrel tablets Stroka tablets
Proposed Referencea Proposed Referencea
Recoveryb (%) 101.31 101.42 100.28 98.87
101.82 102.01 101.35 101.23
100.88 99.14 99.01 101.88
102.52 101.48 98.98 100.84
Mean (x) 101.63 101.01 99.91 100.71
SD 0.71 1.28 1.14 1.30
Variance 0.50 1.63 1.30 1.68
Student’s t-value 0.85 0.93
Variance ratio F-value 3.26 1.29
Tabulated t and F values at p= 0.05 are 2.45 and 9.28, respectively (Miller and Miller, 1993).
a Belal et al. (2009).
b Each result is the average of three separate determinations.
28 N.A. Alarfaj(n= 3) and inter-day (n= 3) accuracy, calculated as % Er,
was found to be within 0.19–0.91% and 0.28–0.71% for Clp,
respectively. The repeatability of the assay was found to be
within 0.33–1.57 (n= 3) at 0.5, 1, and 2 lg ml1. The repro-
ducibility of the assay at the concentration levels was found
to be within 0.48–1.23 lg ml1 (n= 3).
The results of the proposed method were favorably com-
pared with those obtained using the reference method (Belal
et al., 2009). Statistical analysis (Miller and Miller, 1993) of
the results obtained by the proposed and reference methods
showed no signiﬁcant difference in the performance of the
two methods using Student’s t-test and variance ratio F-test
(Table 5). The proposed procedure offers additional advanta-
ges over the reference procedure; in that it is simple and more
sensitive with good accuracy and precision and carried out in
short time (tR of Clp = 6.84 min) with low consumption of
mobile phase (ﬂow rate 0.5 ml min1) compared to the refer-
ence one (1 ml min1). Moreover, it does not need the use ofan internal standard which consumes time for preparation.
The reference method (Belal et al., 2009) depends on formation
of Micellar LC (tR = 13.4 min).
3.3. Applications
3.3.1. Dosage form analysis
The proposed method was successfully applied to the assay of
Clp in commercial tablets (Myogrel and Stroka). The aver-
age percent recoveries of different concentrations were based
on the average of three replicate determinations. The results
shown in Table 6 are in good agreement with those obtained
by the reference one (Belal et al., 2009).
3.3.2. Content uniformity testing
Due to the high precision of the proposed method and its abil-
ity to rapidly estimate the concentration of the drug in a single
tablet extract with sufﬁcient accuracy, the method is ideally
Table 7 Results of content uniformity testing of clopidogrel
tablets using the proposed method.
Parameters Label claima (%)
Myogrel tablets Stroka tablets
100.84 101.32
98.78 100.53
97.64 101.64
99.53 98.48
101.34 101.42
98.68 98.65
97.56 101.48
100.68 97.84
99.35 98.52
101.66 101.61
99.61 100.15
1.47 1.57
Mean (x) 1.48 1.57
% RSD 0.47 0.50
Acceptance value (AV)b 3.53 3.77
Max. allowed AV (LI)b 15
a Each result is the average of three separate determinations.
b USP (2007).
Table 8 Recovery data obtained from different synthetic
mixtures of clopidogrel bisulfate and acetyl salicylic acid.
Mix. No. Clopidogrel bisulfate Acetyl salicylic acid
Added
(lg ml1)
Recoverya (%) Added
(lg ml1)
Recoverya (%)
1 3 97.05 2 101.36
2 1 97.45 1 100.48
3 2 100.67 3 98.82
4 1 99.84 3 97.63
5 2 98.78 4 101.45
6 3 101.68 5 99.77
Mean (x) 99.23 99.92
SD 1.82 1.50
% RSD 1.84 1.50
% Er 0.75 0.61
a Each result is the average of three separate determinations.
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ing process when using conventional assay techniques. The
steps of the test were adopted according to the USP procedure.
The acceptance value (AV) was calculated for each of the com-
mercially available tablets and was found to be smaller than
the maximum allowed acceptance value (LI). The results are
shown in Table 7.
3.3.3. Co-administered drug
The proposed method allowed determination of Clp in
presence of its co-administered drug, acetyl salicylic acid. In
order to assess the validity and applicability of the developed
method, recovery studies were performed by analyzing syn-
thetic mixtures of each drug in different ratios. The mean per-
centage recoveries (±RSD) indicating good accuracy and
precision were found to be 99.23 ± 1.84 for clopidogrel andFigure 5 Clopidogrel and99.92 ± 1.50 for acetyl salicylic acid with retention time
3.44 min for the latter compound (Table 3 and Fig. 5) (see
Table 8).
4. Conclusion
The purpose of this study is to develop and validate a LC
method that allows simple, speciﬁc, accurate and reproducible
determination of clopidogrel in tablets (Myogrel and Stro-
ka). The proposed method is fast, feasible and has a limit
of detection of 0.079 lg ml1 and a limit of quantitation of
0.2 lg ml1.
The proposed method is stability-indicating as it is suitable
for the determination of clopidogrel in presence of its degrada-
tion products under all stress conditions using HCl, NaOH,
H2O2 and light. In addition it is suitable for the determination
of clopidogrel in commercial tablets. Thus, it can be used for
quality control of clopidogrel tablets with excellent application
to content uniformity test. It also offers the possibility to deter-
mine clopidogrel in the presence of the co-administered drug,
acetyl salicylic acid in short time.acetyls chromatogram.
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